American Diabetes Association and Xeris Pharmaceuticals Announce Nationwide Collaboration to Provide Lifesaving Hypoglycemia Education and Awareness

A strategic collaboration formed to raise awareness that all diabetics taking hypoglycemic drugs should take glucagon. Preferably, a preparation that can be used immediately

chicago and arlington, virginia, January 21, 2025 /PRNewswire/ — American Diabetes Association^® (ADA) and Xeris Pharmaceuticals^® Xeris BioPharma Holdings, Inc., a national supporter of the ADA, is implementing a multi-year strategy to reinforce the importance of prescribing glucagon, preferably ready-to-use, to all diabetic patients receiving diabetes treatment. We are pleased to announce this partnership. Insulin and/or insulin secretagogues or patients at high risk for hypoglycemia (also known as hypoglycemia, hypoglycemia) in accordance with the recently updated ADA. Diabetes treatment standards—2025 (standard of care).¹

“Severe hypoglycemia is life-threatening, and diabetics who take hypoglycemic drugs are at risk of hypoglycemia. Therefore, it is important to have a treatment plan that includes having glucagon on hand. “We must act urgently to educate people about sex,” Charles “Chuck” said. hendersonCEO of ADA. “Through this important partnership, we can save lives by ensuring that diabetic patients on insulin have access to glucagon, preferably in a ready-to-use formulation, so they can plan and be prepared.” You can arrange it.”

It is estimated that up to 46% of people with type 1 diabetes and 21% of people with type 2 diabetes who use insulin experience at least one severe hypoglycemia event each year.² Hypoglycemia conservatively accounts for more than 202,000 emergency department visits and approximately 25% hospitalizations annually.³ This is unacceptable. More needs to be done to protect people at risk of severe hypoglycemia.

With support from Xeris, the ADA will develop educational and training resources for healthcare professionals and people with diabetes, as well as a national awareness campaign to educate people about people with diabetes, to address low rates of appropriate glucagon prescribing. I'm trying to correct it. Because of the risk of severe hypoglycemia, you should take glucagon, preferably readily available, as a safety net.

“Severe hypoglycemia is associated with up to a three-fold increased risk of death in people with diabetes.^{4, 5, 6} “Xeris is proud to work with the ADA to encourage the adoption of enhanced clinical practice recommendations for the treatment of severe hypoglycemia.” john shannonCEO of Xeris. “For many at-risk patients, the risks are too high without a safety net. Our mutual commitment is to fight for all patients living with diabetes and ensure they are always prepared. , so that you can confidently face serious hypoglycemic emergencies using the glucagon you have on hand. ”

To learn more about the importance of severe hypoglycemia, preparedness, and treatment options, visit diadiadia.org/severehypo.

About the American Diabetes Association
The American Diabetes Association (ADA) is the nation's leading independent health organization fighting to end diabetes and help people thrive. For 84 years, the ADA has advanced discoveries and research to prevent, manage, treat, and ultimately cure diabetes. 136 million Americans live with diabetes or prediabetes. We fight for them all through advocacy, program development, and education. For more information or to get involved, please visit: diabetes.org Or call 1-800-DIABETES (800-342-2383). Join the fight with us on Facebook (american diabetes association), Facebook in Spanish (american diabetes association), LinkedIn (american diabetes association), Instagram (@DiabetesAssn). If you would like to learn more about how we help everyone living with diabetes, please visit X (@DiabetesAssn).

About Xeris
Xeris (NASDAQ: XERS) is a growth-oriented biopharmaceutical company committed to improving the lives of patients by developing and commercializing innovative products across a variety of therapeutic modalities. Xeris has three commercially available products. Recorlev®, for the treatment of endogenous Cushing's syndrome. Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis® is a proven treatment for primary periodic paralysis. Xeris also has a pipeline of development programs centered around XP-8121, a Phase 3 once-weekly subcutaneous injection for hypothyroidism, and Xeris' technology platforms, XeriSol® and XeriJect®, for partners. We have multiple early stage programs that we leverage. .

The headquarters of Xeris Biopharma Holdings is Chicago, Illinois. For more information, please visit: www.xerispharma.comor follow us on X, LinkedIn, or Instagram.

1. American Diabetes Association Specialty Practice Committee. 6. Glucose Targets and Hypoglycemia: Diabetes Treatment Standards—2025. diabetes care January 1, 2025. 48 (Supplement_1): S128–S145. https://doi.org/10.2337/dc25-S006
2. Stuckey HL, Desai U, King SB et al. The experience of severe hypoglycemic events from the perspective of people with diabetes and their caregivers: “What should I do?” Diabetic drugs. 2022;39(4):e14745. doi:10.1111/dme.14745
3. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Accessed January 8, 2025. https://www.cdc.gov/diabetes/php/data-research/index.html
4. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: report of the American Diabetes Association and Endocrine Society workgroup. diabetes care. 2013;36(5):1384-1395. doi:10.2337/dc12-2480
5. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Vermers RA, Smith SA. Increased mortality in diabetics who report severe hypoglycemia.diabetes care. 2012;35(9):1897-1901. doi:10.2337/dc11-2054
6. Zoungas S, Patel A, Chalmers J et al. Severe hypoglycemia and the risk of vascular events and death.N English J Medicine. 2010;363(15):1410-1418. doi:10.1056/NEJMoa1003795.

contact: virginia kramer(703) 253-4927
[email protected]

Source American Diabetes Association